Table 1.
Patient demographics, characteristics, and treatment patterns by prescription of vericiguat.
| Variable | Overall (n = 228) | Eligible, not prescribed vericiguat (n = 130)a | Prescribed vericiguat (n = 98)b | p-value |
|---|---|---|---|---|
| Age | ||||
| Years, mean (SD) | 66.8 (11.76) | 67.4 (12.21) | 66.0 (11.15) | 0.383 |
| Sex | ||||
| Male sex, n (%) | 150 (65.79) | 88 (67.69) | 62 (63.27) | 0.573 |
| Ethnicity | ||||
| White, n (%) | 137 (60.09) | 76 (58.46) | 61 (62.24) | 0.587 |
| Black, n (%) | 44 (19.30) | 28 (21.54) | 16 (16.33) | 0.397 |
| Hispanic, n (%) | 28 (12.28) | 15 (11.54) | 13 (13.27) | 0.690 |
| Otherc, n (%) | 22 (9.65) | 12 (9.23) | 10 (10.20) | 0.824 |
| US region | ||||
| West, n (%) | 79 (34.65) | 58 (44.62) | 21 (21.43) | <0.001 |
| Northeast, n (%) | 67 (29.39) | 39 (30.00) | 28 (28.57) | |
| Midwest, n (%) | 59 (25.88) | 20 (15.38) | 39 (39.80) | |
| South, n (%) | 23 (10.09) | 13 (10.00) | 10 (10.20) | |
| Insurance status | ||||
| Medicare, n (%) | 128 (56.14) | 75 (57.69) | 53 (54.08) | 0.593 |
| Commercial, n (%) | 72 (31.58) | 46 (35.38) | 26 (26.53) | 0.195 |
| Medicaid, n (%) | 11 (4.82) | 4 (3.08) | 7 (7.14) | 0.213 |
| Otherd, n (%) | 20 (8.77) | 6 (4.62) | 14 (14.29) | 0.016 |
| No insurance coverage | 2 (0.88) | 0 (0.00) | 2 (2.04) | 0.184 |
| Top 5 comorbidities | ||||
| Hypertension, n (%) | 126 (55.26) | 81 (62.31) | 45 (45.92) | 0.016 |
| Hyperlipidemia, n (%) | 102 (44.74) | 68 (52.31) | 34 (34.69) | 0.011 |
| Diabetes, n (%) | 73 (32.02) | 48 (36.92) | 25 (25.51) | 0.085 |
| Osteoarthritis, n (%) | 37 (16.23) | 25 (19.23) | 12 (12.24) | 0.204 |
| Depression, n (%) | 35 (15.35) | 19 (14.62) | 16 (16.33) | 0.716 |
| Time since HF diagnosise | ||||
| Mean (SD) years | 2.9 (2.87) | 3.2 (3.19) | 2.4 (2.23) | 0.072 |
| HF hospitalizationf | ||||
| Never, n (%) | 42 (20.00) | 0 (0.00)g | 42 (52.76) | <0.001 |
| Within past 6 months, n (%) | 22 (11.17) | 18 (14.63) | 4 (5.41) | |
| More than 6 months ago, n (%) | 133 (65.51) | 105 (85.37) | 28 (37.84) | |
| Time since most recent hospitalization (days) | ||||
| Median (IQR) | 90.5 (22.0, 220.5) | 84.5 (17.0, 185.0) | 201.0 (62.0, 242.0) | 0.498 |
| EF at time of visit | ||||
| Mean (SD) | 37.71 (8.43) | 34.69 (5.83) | 41.71 (9.62) | <0.001 |
| Current treatment | ||||
| Angiotensin converting enzyme inhibitor (ACEi), n (%) | 66 (28.95) | 53 (40.77) | 13 (13.27) | <0.001 |
| Angiotensin receptor blockers (ARB), n (%) | 32 (14.04) | 26 (20.00) | 6 (6.12) | 0.003 |
| ACEi/ARB, n (%) | 90 (39.47) | 71 (54.62) | 19 (19.39) | <0.001 |
| Angiotensin receptor blocker + neprilysin inhibitor (ARNi), n (%) | 94 (41.23) | 62 (47.69) | 32 (32.65) | 0.030 |
| Beta-blockers, n (%) | 163 (71.49) | 118 (90.77) | 45 (45.92) | <0.001 |
| Mineralocorticoid receptor antagonists (MRA), n (%) | 68 (29.82) | 37 (28.46) | 31 (31.63) | 0.662 |
| Sodium-glucose cotransporter-2 inhibitors (SGLT2i), n (%) | 62 (27.19) | 37 (28.46) | 25 (25.51) | 0.654 |
| Receiving triple therapy | ||||
| Yes, n (%)h | 28 (12.28) | 17 (13.08) | 11 (11.22) | 0.839 |
| No, n (%) | 200 (87.72) | 113 (86.92) | 87 (88.78) | |
| Receiving quadruple GDMT | ||||
| Yes, n (%)i | 32 (14.04) | 20 (15.38) | 12 (12.24) | 0.566 |
| No, n (%) | 196 (86.0) | 110 (84.62) | 86 (87.76) | |
BMI, body mass index; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GDMT, guideline-directed medical therapy; HF, heart failure; IQR, interquartile range; NT-proBNP, N-terminal pro–B-type natriuretic peptide; SD, standard deviation; US, United States. Data points which add to >100% are due to the question being multiple choice and some respondents selecting >1 option.
Eligibility criteria for “Eligible but not currently prescribed vericiguat:” Patients eligible but not being prescribed vericiguat at the time of survey had a history of ≥1 HFH at any time, an EF <45% at their last assessment, were part of the random sample, and had no evidence of chronic kidney disease Stage 5 or need for dialysis.
Eligibility criteria for “Currently prescribed vericiguat:” HF diagnosis and being prescribed vericiguat at the time of survey.
Comprised of Native American, Asian (Indian subcontinent), South-East Asian, Asian (other), Middle Eastern and Other not included in the list.
Comprised of Health Insurance Exchange Plan, Cobra (continuation coverage), Non-Medicare Retired Benefit and Tricare/Veterans Healthcare.
Overall, 175 patients had data stating how long it had been since they were diagnosed with HF, 104 among patients eligible but not prescribed vericiguat, and 71 among patients who were prescribed vericiguat.
Overall, 210 patients had data about previous HFH, 130 among patients eligible but not prescribed vericiguat, and 80 among patients who were prescribed vericiguat.
Inclusion criteria for patients eligible but not prescribed vericiguat included history of HFH. As a result, all patients in this group have ≥1 HFH in their medical record.
Triple therapy was defined as angiotensin receptor neprilysin inhibitors (ARNi) or angiotensin-converting enzyme inhibitors (ACEi) or angiotensin ii receptor blockers (ARB), and beta-blockers, and mineralocorticoid receptor antagonists (MRA). Note that patients receiving quadruple therapy which included the triple treatment defined here were excluded from these analyses.
Quadruple GDMT was defined as use of ARNi or ACEi or ARB, and beta-blockers, and MRA, and sodium-glucose cotransporter-2 inhibitors (SGLT2i).